2h
Zacks.com on MSNExpanding Diabetes Business Supports ABT Stock, FX Issues StayAbbott’s ABT diversified business portfolio is well-positioned to drive continued momentum in 2025. Yet, the international ...
Abbott (NYSE: ABT) recently reported its Q4 results, with revenues marginally below and earnings meeting the street expectations. The company reported revenue of $10.97 billion and earnings of $1. ...
ABT currently has a PEG ratio of 2.43. Another notable valuation metric for AHCO is its P/B ratio of 0.79. The P/B ratio pits a stock's market value against its book value, which is defined as ...
Abbott Laboratories’ ABT growth in the fourth quarter of 2024 ... Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners ...
We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are ...
Shares of Abbott Laboratories ABT slipped 2.91% to $128.22 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.36% to 6,083 ...
75.18% of the stock is currently owned by institutional investors and hedge funds. ABT has been the topic of several research reports. Jefferies Financial Group upped their price objective on ...
ABT currently has a PEG ratio of 2.43. Another notable valuation metric for HAE is its P/B ratio of 4.28. Investors use the P/B ratio to look at a stock's market value versus its book value ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results